Caitlin John’s GSK GSK Stock Holding History

Caitlin John’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-2	Closed	-$86	–	950
2025 Q3	$86	Buy	+2	New	+$78	﹤0.01%	864
2025 Q1	–	Sell	-2	Closed	-$68	–	397
2024 Q4	$68	Hold	2	–	–	﹤0.01%	844
2024 Q3	$70	Hold	2	–	–	﹤0.01%	833
2024 Q2	$77	Hold	2	–	–	﹤0.01%	833
2024 Q1	$86	Hold	2	–	–	﹤0.01%	863
2023 Q4	$75	Buy	+2	New	+$72	﹤0.01%	872

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Caitlin John's GSK Position: Q4 2025 in Review

Caitlin John sold out of GSK (GSK) in Q4 2025, closing a stake of 2 shares — an estimated $86 sold.

Caitlin John first reported a position in GSK in Q4 2023 and held it in 6 quarters. The position peaked at $86 in Q3 2025. 995 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Caitlin John reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Caitlin John sold 2 GSK shares in Q4 2025, an estimated $86.
Caitlin John first reported a position in GSK in Q4 2023 and held it in 6 quarters.
Caitlin John's GSK position peaked at $86 in Q3 2025.
995 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Caitlin John's 13F filing for Q4 2025, filed 18 Feb 2026.